Literature DB >> 6107592

Double-blind, controlled trial of immunosuppression in treatment of multiple sclerosis.

J Mertin, S C Knight, P Rudge, E J Thompson, M J Healy.   

Abstract

30 multiple sclerosis patients in a double-blind, controlled trial were given immunosuppressive treatment consisting of antilymphocyte globulin, prednisolone, and azathioprine, or placebo. After 15 months of treatment the immunosuppressed group had a reduction in the number of relapses and some retardation of the clinical course of the disease (p < 0.06). The beneficial effect was seen only in females.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6107592     DOI: 10.1016/s0140-6736(80)92107-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  5 in total

1.  Multiple sclerosis, hyperbaric oxygen and cancer.

Authors:  W I McDonald; J Mertin
Journal:  Br Med J (Clin Res Ed)       Date:  1984-06-23

2.  Autoimmune optic neuropathy: evaluation and treatment.

Authors:  M J Kupersmith; R M Burde; F A Warren; T G Klingele; L P Frohman; H Mitnick
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-11       Impact factor: 10.154

3.  Effects of anti-lymphocytic globulin in human subjects.

Authors:  M F Heyworth
Journal:  Immunology       Date:  1981-08       Impact factor: 7.397

Review 4.  Azathioprine for multiple sclerosis.

Authors:  I Casetta; G Iuliano; G Filippini
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

5.  Cell number requirements for lymphocyte stimulation in vitro: changes during the course of multiple sclerosis and the effects of immunosuppression.

Authors:  S C Knight; B Harding; S Burman; J Mertin
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.